Skip to main content Accessibility help

Review of recent clinical studies with olanzapine

  • Gary D. Tollefson (a1) and Amy J. Kuntz (a1)


Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments. Clinical investigations employing olanzapine have demonstrated a number of potential therapeutic advantages in reference not only to placebo but also to contemporary drug standards in the management of psychosis. This paper reviews data on the pharmacokinetics, efficacy and safety of olanzapine, its benefits for quality of life, and economic aspects to assist clinicians in determining where they can usefully employ it.


Corresponding author

Correspondence: Dr G. D. Tollefson, Vice President, Lilly Research Laboratories, Lilly Corporate Center, Drop Code 0538, Indianapolis, IN 46285, USA


Hide All
Andreasen, N. C. (1982) Negative symptoms in schizophrenia. Archives of General Psychiatry, 39, 784788.
Barnes, T. R. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672676.
Beasley, C. M., Jr, Sanger, T., Satterlee, W., et al (1996a) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology, 124, 159167.
Beasley, C. M., Tollefson, G. D., Tran, P. V., et al (1996b) Olanzapine versus placebo and haloperidol: acute-phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 105118.
Beasley, C. M., Hamilton, S. H., Crawford, A. M., et al (1997a) Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 7, 125137.
Beasley, C. M., Tollefson, G. D. & Tran, P. V. (1997b) Efficacy of olanzapine: an overview of pivotal clinical studies. Journal of Clinical Psychiatry, 58 (suppl. 10), 712.
Crawford, A. M. K., Beasley, C. M. Jr & Tollefson, G. D. (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research, 26, 4154.
Dellva, M. A., Tran, P., Tollefson, G. D., et al (1997) Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatric Services, 48, 15711577.
Glazer, W. M. (1997) Olanzapine and the new generation of antipsychotic agents: patterns of use. Journal of Clinical Psychiatry, 58 (suppl. 10), 1821.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology (revised version). Bethesda, MD: US Department of Health, Education and Welfare.
Harrow, M., Yonan, C. A., Sands, J. R., et al (1994) Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophrenia Bulletin, 20, 327338.
Heinrichs, D. W., Hanlon, T. E. & Carpenter, W. T. (1984) The Quality of Life Scale: an instrument for rating schizophrenia deficit syndrome. Schizophrenia Bulletin, 10, 388398.
Kay, S. R., Opler, L. A. & Fiszbein, A. (1986) Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems Inc.
Nemeroff, C. B. (1997) Dosing the antipsyc hotic medication olanzapine. Journal of Clinical Psychiatry, 58 (suppl. 10), 4549.
Pilowsky, L. S., Busatto, G. F., Taylor, M., et al (1996) Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine – a 1231 1BZM single photon emission tomography (SPET) study. Psychopharmacology, 124, 148153.
Tollefson, G. D. & Sanger, T. M. (1997) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry, 154, 466474.
Tollefson, G. D., Beasley, C. M., Jr, Tamura, R. N., et al (1997a) A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry, 154, 12481254.
Tollefson, G. D., Beasley, C. M., Tran, P. V., et al (1997b) Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457465.
Tollefson, G. D., Tran, P. V., Birkett, M., et al (1997c) Treatment failure with clozapine. Can olanzapine be the alternative therapy? Schizophrenia Research, 24, 191.
Tollefson, G. D., Sanger, T. M., Lu, Y., et al (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Archives of General Psychiatry, 55, 250258.
Tran, P. V., Hamilton, S. H., Kuntz, A. J., et al (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17, 407418.
Woerner, M. G., Mannuzza, S. & Kane, J. M. (1988) Anchoring the BPRS: an aid to improved reliability. Psychopharmacology Bulletin, 24, 112117.


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Review of recent clinical studies with olanzapine

  • Gary D. Tollefson (a1) and Amy J. Kuntz (a1)
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *